# RECLAIM STUDY: A Phase 2 Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight

> **NCT06987513** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Altimmune, Inc.** · enrollment: 100 (actual)

## Conditions studied

- Alcohol Use Disorder (AUD)

## Interventions

- **DRUG:** Pemvidutide
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06987513
- **Lead sponsor:** Altimmune, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-05-15
- **Primary completion:** 2026-05
- **Final completion:** 2026-06
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2025-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06987513

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06987513, "RECLAIM STUDY: A Phase 2 Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT06987513. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*